IRONDisc Medicine, Inc.

Healthcare
$62.08+2.1% 1Y

Price

+2.1%1Y

End-of-day closes, not the intraday tick.

RyuScore

Weak, higher than 9% of companies
10/100
Seven criteria, weighted: see how it is built

The five questions

2 of 5 available

Only two of the five can be answered for IRON today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. We have assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.

In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR

P/En/a
Market value$2.68B
1 year+2.1%
5 years-54%

Charts

As reported to the SEC, without any scoring.

The next results filing is expected around Nov 5, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Sep 10, 2026On September 9, 2026, the Company announced initial results from the RESTORE-PV clinical trial of DISC-3405 in patients with PV. The Phase 2, multi-center, open-label RESTORE-PV trial enrolled 40 adult participants with PV, including 20 participants in Cohort A and 20 participants in Cohort B. In the trial, following …Regulation FD disclosure · Form 8-K
  2. Jul 30, 2026Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
  3. Jun 30, 2026On June 25, 2026, Disc Medicine, Inc. (the “Company”) entered into a First Amendment to Loan Agreement (the “Amendment”) to the Loan and Security Agreement dated as of November 6, 2024 (as amended, the “Loan Agreement”) among the Company, the lender party thereto and Hercules Capital, Inc., as administrative agent and …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

On our screens:Most shorted stocks

Biotechnology

Ranks #108 of 196 by RyuScore

Compare peers
KLRA+16%
Kailera Therapeutics, Inc.
CLDX+2.1%
Celldex Therapeutics, Inc.
TARS+1.2%
Tarsus Pharmaceuticals, Inc.
TRVI+3.0%
Trevi Therapeutics, Inc.
RARE+1.4%
Ultragenyx Pharmaceutical Inc.
VERA+0.44%
Vera Therapeutics, Inc.